group VI iPLA₂ Antibody (E-8): sc-166616

group VI iPLA2 Antibody (E-8) is a mouse monoclonal IgG2b antibody that detects group VI iPLA2 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). group VI iPLA2 plays a crucial role in lipid metabolism by catalyzing the hydrolysis of phospholipids, which is essential for maintaining cellular membrane integrity and signaling pathways. group VI iPLA2 is primarily localized in the cytoplasm and interacts with various membrane components, influencing the dynamics of membrane phospholipid composition. The human gene encoding group VI iPLA2 is located on chromosome 22q13.1, and expression is tightly regulated, reflecting importance in physiological processes such as inflammation and cell signaling. Additionally, the presence of multiple isoforms, including those that lack the catalytic domain, suggests a complex regulatory mechanism that may modulate group VI iPLA2 activity, further underscoring significance in cellular functions. anti-group VI iPLA2 antibody (E-8) is an invaluable tool for researchers studying lipid metabolism and implications in various biological processes and diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

group VI iPLA₂ Antibody (E-8) References:

1. Role of calcium-independent phospholipases (iPLA(2)) in phosphatidylcholine metabolism.  |  Chiu, CH. and Jackowski, S. 2001. Biochem Biophys Res Commun. 287: 600-6. PMID: 11563837
2. Identification and distribution of endoplasmic reticulum iPLA2.  |  Kinsey, GR., et al. 2005. Biochem Biophys Res Commun. 327: 287-93. PMID: 15629460
3. Mitochondrial iPLA2 activity modulates the release of cytochrome c from mitochondria and influences the permeability transition.  |  Gadd, ME., et al. 2006. J Biol Chem. 281: 6931-9. PMID: 16407316
4. Passive calcium leak via translocon is a first step for iPLA2-pathway regulated store operated channels activation.  |  Flourakis, M., et al. 2006. FASEB J. 20: 1215-7. PMID: 16611832
5. iPLA2, a novel determinant in Ca2+- and phosphorylation-dependent S100A8/A9 regulated NOX2 activity.  |  Schenten, V., et al. 2010. Biochim Biophys Acta. 1803: 840-7. PMID: 20219570
6. Proinflammatory treatment of astrocytes with lipopolysaccharide results in augmented Ca2+ signaling through increased expression of via phospholipase A2 (iPLA2).  |  Strokin, M., et al. 2011. Am J Physiol Cell Physiol. 300: C542-9. PMID: 21178110
7. A mouse model of in vivo chemical inhibition of retinal calcium-independent phospholipase A2 (iPLA2).  |  Saab-Aoudé, S., et al. 2013. Biochimie. 95: 903-11. PMID: 23266358
8. Inhibition of iPLA2 β and of stretch-activated channels by doxorubicin alters dystrophic muscle function.  |  Ismail, HM., et al. 2013. Br J Pharmacol. 169: 1537-50. PMID: 23849042
9. Impaired corticostriatal LTP and depotentiation following iPLA2 inhibition is restored following acute application of DHA.  |  Mazzocchi-Jones, D. 2015. Brain Res Bull. 111: 69-75. PMID: 25562715
10. Leptin suppresses non-apoptotic cell death in ischemic rat cardiomyocytes by reduction of iPLA(2) activity.  |  Takatani-Nakase, T. and Takahashi, K. Biochem Biophys Res Commun. 463: 13-7. PMID: 25979360

The preferred group VI iPLA₂ antibody is group VI iPLA₂ Antibody (D-4): sc-376563.